Collecting Duct Carcinoma

  • Hendrik Van PoppelEmail author
  • Evelyne Lerut
  • Raymond Oyen
  • Maria Debiec-Rychter
  • Herlinde Dumez
  • Maarten Albersen
  • Steven Joniau


Collecting duct carcinoma (CDC) of the kidney is a rare variant of renal cell carcinoma (RCC) with an extremely poor prognosis as most cases are metastatic at the time of diagnosis. RCC is a clinically, histologically and genetically heterogeneous group of tumours. The different subtypes of RCC are classified according to the cells of origin in the different parts of the nephron. Conventional (clear cell) RCC and papillary RCC show alterations linked to the proximal tubules, while chromophobe RCC and CDC are presumed to originate from the collecting duct epithelium (intercalated cells and principal cells of the collecting ducts, respectively). The collecting ducts in the kidney are also known as the Bellini’s ducts, named after the Italian physician Lorenzo Bellini (1643–1704) who described these tubes for the first time (ref: This explains why CDC is also known as Bellini duct carcinoma. Of all renal neoplasms, CDC is the most aggressive with no established treatment guidelines [1, 2].


  1. 1.
    Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Polascik TJ, Cairns P, Epstein JI, Fuzesi L, Ro JY, Marshall FF, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res. 1996;56(8):1892–5.PubMedGoogle Scholar
  3. 3.
    Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976;38(6):2469–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181(2):125–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology. 1986;10(11):1131–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Tumours of the urinary and male genital organs. Lyon: IARC; 2004.Google Scholar
  8. 8.
    Cornelis F, Helenon O, Correas JM, Lemaitre L, Andre M, Meuwly JY, et al. Tubulocystic renal cell carcinoma: a new radiological entity. Eur Radiol. 2016;26(4):1108–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wright JL, Risk MC, Hotaling J, Lin DW. Effect of collecting duct histology on renal cell cancer outcome. J Urol. 2009;182(6):2595–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Abern MR, Tsivian M, Polascik TJ, Coogan CL. Characteristics and outcomes of tumors arising from the distal nephron. Urology. 2012;80(1):140–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Karakiewicz PI, Trinh QD, Rioux-Leclercq N, de la Taille A, Novara G, Tostain J, et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007;52(4):1140–5.PubMedCrossRefGoogle Scholar
  13. 13.
    May M, Ficarra V, Shariat SF, Zigeuner R, Chromecki T, Cindolo L, et al. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. J Urol. 2013;190(2):458–63.PubMedCrossRefGoogle Scholar
  14. 14.
    Tokuda N, Naito S, Matsuzaki O, Nagashima Y, Ozono S, Igarashi T. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol. 2006;176(1):40–3. discussion 3CrossRefGoogle Scholar
  15. 15.
    Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Genitales) study. J Urol. 2007;177(5):1698–702.PubMedCrossRefGoogle Scholar
  16. 16.
    Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–81.CrossRefGoogle Scholar
  17. 17.
    Srigley JR, Eble JN. Collecting duct carcinoma of kidney. Semin Diagn Pathol. 1998;15(1):54–67.PubMedGoogle Scholar
  18. 18.
    Pepek JM, Johnstone PA, Jani AB. Influence of demographic factors on outcome of collecting duct carcinoma: a surveillance, epidemiology, and end results (SEER) database analysis. Clin Genitourin Cancer. 2009;7(2):E24–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Oyen R, Verswijvel G, Van Poppel H, Roskams T. Primary malignant renal parenchymal epithelial neoplasms. Radiologic-pathologic correlations. Eur Radiol. 2000;10(Suppl 2):S 231–43.Google Scholar
  20. 20.
    Pickhardt PJ, Siegel CL, McLarney JK. Collecting duct carcinoma of the kidney: are imaging findings suggestive of the diagnosis? AJR Am J Roentgenol. 2001;176(3):627–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Yoon SK, Nam KJ, Rha SH, Kim JK, Cho KS, Kim B, et al. Collecting duct carcinoma of the kidney: CT and pathologic correlation. Eur J Radiol. 2006;57(3):453–60.PubMedCrossRefGoogle Scholar
  22. 22.
    Hu Y, Lu GM, Li K, Zhang LJ, Zhu H. Collecting duct carcinoma of the kidney: imaging observations of a rare tumor. Oncol Lett. 2014;7(2):519–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhu Q, Wu J, Wang Z, Zhu W, Chen W, Wang S. The MSCT and MRI findings of collecting duct carcinoma. Clin Radiol. 2013;68(10):1002–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of collecting duct carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2002;17(4):1329–34.PubMedGoogle Scholar
  25. 25.
    Kuroda N, Toi M, Hiroi M, Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol. 2003;18(2):487–94.PubMedGoogle Scholar
  26. 26.
    Matei DV, Rocco B, Varela R, Verweij F, Scardino E, Renne G, et al. Synchronous collecting duct carcinoma and papillary renal cell carcinoma: a case report and review of the literature. Anticancer Res. 2005;25(1B):579–86.PubMedGoogle Scholar
  27. 27.
    Dobronski P, Czaplicki M, Kozminska E, Pykalo R. Collecting (Bellini) duct carcinoma of the kidney—clinical, radiologic and immunohistochemical findings. Int Urol Nephrol. 1999;31(5):601–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Orsola I. Renal collecting (Bellini) duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma. Urology. 2005;65(1):49–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol. 2009;22(Suppl 2):S2–S23.PubMedCrossRefGoogle Scholar
  30. 30.
    Oyen R, Verswijvel G, Van Poppel H, Roskams T. Primary malignant renal parenchymal epithelial neoplasms. Eur Radiol. 2001;11(Suppl 2):S205–S17.Google Scholar
  31. 31.
    Kobayashi N, Matsuzaki O, Shirai S, Aoki I, Yao M, Nagashima Y. Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol. 2008;39(9):1350–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Albadine R, Schultz L, Illei P, Ertoy D, Hicks J, Sharma R, et al. PAX8 (+)/p63 (−) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol. 2010;34(7):965–9.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Gonzalez-Roibon N, Albadine R, Sharma R, Faraj SF, Illei PB, Argani P, et al. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas. Hum Pathol. 2013;44(12):2651–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Füzesi L, Cober M, Mittermayer C. Collecting duct carcinoma: cytogenetic characterization. Histopathology. 1992;21(2):155–60.PubMedCrossRefGoogle Scholar
  35. 35.
    Schoenberg M, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, et al. Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer. 1995;12(1):76–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Verdorfer I, Culig Z, Hobisch A, Bartsch G, Hittmair A, Duba HC, et al. Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation. Int J Oncol. 1998;13(3):461–4.PubMedGoogle Scholar
  37. 37.
    Antonelli A, Portesi E, Cozzoli A, Zanotelli T, Tardanico R, Balzarini P, et al. The collecting duct carcinoma of the kidney: a cytogenetical study. Eur Urol. 2003;43(6):680–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Parker R, Reeves HM, Sudarshan S, Wolff D, Keane T. Abnormal fluorescence in situ hybridization analysis in collecting duct carcinoma. Urology. 2005;66(5):1110.PubMedCrossRefGoogle Scholar
  39. 39.
    Cavazzana AO, Prayer-Galetti T, Tirabosco R, Macciomei MC, Stella M, Lania L, et al. Bellini duct carcinoma. A clinical and in vitro study. Eur Urol. 1996;30(3):340–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Gregon-Romero MA, Morell-Quadreny L, Llombart-Bosch A. Cytogenetic analysis of three primary Bellini duct carcinoma. Genes Chromosomes Cancer. 1996;15:170–2.CrossRefGoogle Scholar
  41. 41.
    Becker F, Junker K, Parr M, Hartmann A, Fussel S, Toma M, et al. Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS One. 2013;8(10):e78137.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Marin-Aguilera M, Mengual L, Ribal MJ, Musquera M, Ars E, Villavicencio H, et al. Utility of fluorescence in situ hybridization as a non-invasive technique in the diagnosis of upper urinary tract urothelial carcinoma. Eur Urol. 2007;51(2):409–15. discussion 15PubMedCrossRefGoogle Scholar
  43. 43.
    Fadl-Elmula I, Gorunova L, Mandahl N, Elfving P, Lundgren R, Rademark C, et al. Cytogenetic analysis of upper urinary tract transitional cell carcinomas. Cancer Genet Cytogenet. 1999;115(2):123–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Junker K, Weirich G, Amin MB, Moravek P, Hindermann W, Schubert J. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res. 2003;162:169–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC Jr, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res. 2002;62(4):957–60.PubMedGoogle Scholar
  46. 46.
    Meloni-Ehrig AM. Renal cancer: cytogenetic and molecular genetic aspects. Am J Med Genet. 2002;115(3):164–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D’Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012;72(1):112–21.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012;72(20):5273–84.PubMedCrossRefGoogle Scholar
  49. 49.
    Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, et al. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 2010;49(7):610–9.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Pal SK, Choueiri TK, Wang K, Khaira D, Karam JA, Van Allen E, et al. Characterization of clinical cases of collecting duct carcinoma of the kidney assessed by comprehensive genomic profiling. Eur Urol. 2016;70(3):516–21.PubMedCrossRefGoogle Scholar
  51. 51.
    Wang JZ, Papanicolau-Sengos A, Chintala S, Wei L, Liu B, Hu Q. Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget. 2016;7(21):29901–15. Scholar
  52. 52.
    Dason S, Allard C, Sheridan-Jonah A, Gill J, Jamshaid H, Aziz T, Kajal B, Kapoor A. Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol. 2013;20:223–32.CrossRefGoogle Scholar
  53. 53.
    Kwon KA, Oh SY, Kim HY, Kim HS, Lee HY, Kim TM, et al. Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee. Cancer Res Treat. 2014;46(2):141–7.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Mejean A, Roupret M, Larousserie F, Hopirtean V, Thiounn N, Dufour B. Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma? J Urol. 2003;169(4):1287–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer. 2002;94(1):111–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Barrascout E, Beuselinck B, Ayllon J, Battig B, Moch H, Teghom C, et al. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab. Am J Case Rep. 2012;13:1–2.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Pécuchet N, Bigot F, Gachet J, Massard C, Albiges L, Teghom C, et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol. 2013;24(12):2963–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Bagrodia A, Gold R, Handorf C, Liman A, Derweesh IH. Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney. Can J Urol. 2008;15(6):4425–7.PubMedGoogle Scholar
  59. 59.
    Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology. 2001;58(6):1058.PubMedCrossRefGoogle Scholar
  60. 60.
    Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–84.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Cancer Treat Rev. 2015;41(2):114–21.PubMedCrossRefGoogle Scholar
  62. 62.
    Staehler M, Haseke N, Schoppler G, Stadler T, Karl A, Siebels M, et al. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib. Eur J Med Res. 2008;13(11):531–5.PubMedGoogle Scholar
  63. 63.
    Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol. 2011;16(2):153–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Procopio G, Verzoni E, Iacovelli R, Colecchia M, Torelli T, Mariani L. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol. 2012;16(3):464–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie. 2009;32(1–2):44–6.PubMedGoogle Scholar
  66. 66.
    Zhao RN, Nie LH, Gong R, Wang JZ, Wazir R, Liu LR, et al. Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature. Int Urol Nephrol. 2013;45(4):1017–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Wang X, Hao J, Zhou R, Zhang X, Yan T, Ding D, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of five cases. Diagn Pathol. 8:96.Google Scholar
  68. 68.
    Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, et al. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002;167(1):71–4.PubMedCrossRefGoogle Scholar
  69. 69.
    Kennedy SM, Merino MJ, Linehan WM, Roberts JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol. 1990;21(4):449–56.PubMedCrossRefGoogle Scholar
  70. 70.
    Rumpelt HJ, Storkel S, Moll R, Scharfe T, Thoenes W. Bellini duct carcinoma: further evidence for this rare variant of renal cell carcinoma. Histopathology. 1991;18(2):115–22.PubMedCrossRefGoogle Scholar
  71. 71.
    Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, Deshpande A, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Ciszewski S, Jakimow A, Smolska-Ciszewska B. Collecting (Bellini) duct carcinoma: a clinical study of a rare tumour and review of the literature. Can Urol Assoc J. 2015;9(9–10):E589–93.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Hendrik Van Poppel
    • 1
    Email author
  • Evelyne Lerut
    • 2
  • Raymond Oyen
    • 3
  • Maria Debiec-Rychter
    • 4
  • Herlinde Dumez
    • 5
  • Maarten Albersen
    • 1
  • Steven Joniau
    • 1
  1. 1.Department of UrologyUniversity Hospitals, KU LeuvenLeuvenBelgium
  2. 2.Department of PathologyUniversity Hospitals, KU LeuvenLeuvenBelgium
  3. 3.Department of RadiologyUniversity Hospitals, KU LeuvenLeuvenBelgium
  4. 4.Department of GeneticsUniversity Hospitals, KU LeuvenLeuvenBelgium
  5. 5.Department of Medical OncologyUniversity Hospitals, KU LeuvenLeuvenBelgium

Personalised recommendations